Moving From Missed to Managed: Evidence-Based Recognition and Treatment of Tardive Dyskinesia

Tardive dyskinesia (TD) is often missed or mistaken for other drug-induced movement disorders, even though most clinicians who prescribe antipsychotics will encounter it. This session covers how to recognize TD and tell it apart from acute extrapyramidal symptoms, how to apply AIMS-based screening across outpatient, inpatient, telehealth, and long-term care settings, and the pathophysiology behind prevention, risk mitigation, and supportive management. Attendees will leave able to evaluate FDA-approved treatments, including VMAT2 inhibitors, by weighing patient-specific factors, formulation, safety, tolerability, and real-world evidence.